LONDON (ShareCast) - (Sharecast News) - Ondine Biomedical announced the appointment of Alan Thomas as its interim chief financial officer on Friday, with immediate effect, following the departure of Michael Behlke, who was stepping down from his role as CFO and chief operating officer for personal reasons.
The AIM-traded company thanked Behlke for his service, and confirmed that his chief operating officer responsibilities would be absorbed by the existing executive team.

It said Thomas was bringing more than 25 years of financial leadership experience across the healthcare, biotechnology, and public infrastructure sectors, including senior roles at Maximus Canada, BC Transit, and BC Emergency Health Services.

He had also supported several high-growth firms through key strategic phases such as initial public offerings and investor relations.

Ondine said Thomas's appointment came at a critical juncture, as it advanced the commercial expansion of its light-activated antimicrobial technology, with his expertise expected to enhance financial governance and strategic planning during the company's next stage of growth.

"Ondine is entering an exciting phase of development, with growing momentum behind its breakthrough technology," said Alan Thomas.

"I'm looking forward to working with the team to help drive the company's strategic and financial objectives forward."

At 0802 BST, shares in Ondine Biomedical were down 3.89% at 8.65p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE